Four series of new acridine derivatives of anticipated antitumor
activity have been designed and synthesized. The first series
belongs to 4-substituted phenylhydrazinocarbonylmethyl 9-oxo-
9,10-dihydroacridine-4-carboxylate 10a-h. The second series consists of phenylhydrazinocarbonylmethyl 9-(4-substituted
phenyl)aminoacridine-4-carboxylate 12a-k, while the third series
comprises 4-substituted phenylcarbamoylmethyl 9-(4-substituted
phenyl)aminoacridine-4-carboxylate 15a-k. The fourth one belongs
to phenylcarbamoylmethyl 9-(4-substituted phenyl)aminoacridine-
4- carboxylate 17a-j. The chemical structure of synthesized
compounds was elucidated by spectral data and elemental analysis.
Seventeen selected compounds (10a, 10g, 10h, 12a, 12d, 12g, 12h,
12k, 15a, 15c, 15g, 15h, 15k, 17a, 17f, 17g and 17j) were tested
against breast cancer cell line (MCF7) and eight compounds (12g,
12h, 12k, 15g, 15h, 17f, 17g, 17j) were found to exhibit significant
antitumor activity